Literature DB >> 15349798

Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.

Anna Kuryliszyn-Moskal1, Piotr Adrian Klimiuk, Stanislaw Sierakowski.   

Abstract

Systemic sclerosis (SSc) is a chronic, multisystemic, autoimmune disease characterised by vascular changes and varying degrees of fibrosis of the skin and visceral organs. Organ systemic involvement in SSc is associated with an altered function of endothelial cells, perivascular infiltrating mononuclear cells and interstitial fibrosis. To evaluate the relationship between systemic manifestations and immunological markers of endothelial cell activation, serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) were determined by an enzyme-linked immunosorbent assay in 31 SSc patients and in 30 healthy controls. In comparison with the control group, higher serum concentrations of sVCAM-1, sE-selectin, VEGF and ET-1 were detected in SSc patients (in all cases p<0.001). Elevated concentrations of sVCAM-1 (p<0.05), sE-selectin (p<0.05), VEGF (p<0.05) and ET-1 (p<0.01) dominated in the serum of SSc patients with organ systemic involvement compared to those without systemic manifestation of the disease. These results suggest that the serum levels of sVCAM-1, sE-selectin, VEGF and ET-1 may reflect the extent of internal organ involvement in SSc patients and point to a pathogenic role of these molecules in systemic manifestation of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349798     DOI: 10.1007/s10067-004-0987-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.

Authors:  K Yamane; H Ihn; M Kubo; N Yazawa; K Kikuchi; Y Soma; K Tamaki
Journal:  J Am Acad Dermatol       Date:  2000-01       Impact factor: 11.527

Review 2.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease.

Authors:  Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2003-05

3.  Angiogenesis: a critical process in the pathogenesis of RA--a role for VEGF?

Authors:  E M Paleolog
Journal:  Br J Rheumatol       Date:  1996-10

Review 4.  Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease.

Authors:  G Krishnaswamy; J Kelley; L Yerra; J K Smith; D S Chi
Journal:  J Interferon Cytokine Res       Date:  1999-02       Impact factor: 2.607

5.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

6.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

7.  Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.

Authors:  C P Denton; M C Bickerstaff; X Shiwen; M T Carulli; D O Haskard; R M Dubois; C M Black
Journal:  Br J Rheumatol       Date:  1995-11

9.  Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis.

Authors:  A D Blann; A Herrick; M I Jayson
Journal:  Br J Rheumatol       Date:  1995-09

10.  Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.

Authors:  Sule Apras; Ihsan Ertenli; Zeynep Ozbalkan; Sedat Kiraz; M Akif Ozturk; Ibrahim C Haznedaroglu; Veli Cobankara; Salih Pay; Meral Calguneri
Journal:  Arthritis Rheum       Date:  2003-08
View more
  44 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 2.  T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.

Authors:  Francesco Del Galdo; Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 3.  [Laboratory diagnostics for systemic sclerosis].

Authors:  R Mierau; A Roers; E Genth
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

Review 4.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

5.  Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels.

Authors:  Serena Vettori; Giovanna Cuomo; Michele Iudici; Virginia D'Abrosca; Veronica Giacco; Giusi Barra; Raffaele De Palma; Gabriele Valentini
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

Review 6.  [Current pathophysiological aspects of systemic sclerosis].

Authors:  T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 7.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

8.  Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients.

Authors:  Mariusz Ciołkiewicz; Anna Kuryliszyn-Moskal; Piotr Adrian Klimiuk
Journal:  Clin Rheumatol       Date:  2009-11-12       Impact factor: 2.980

9.  Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension.

Authors:  Melahat Melek Oguz; Ayse Deniz Oguz; Cihat Sanli; Ayhan Cevik
Journal:  Tex Heart Inst J       Date:  2014-04-01

10.  Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells.

Authors:  Shoukang Zhu; Sarah Evans; Bin Yan; Thomas J Povsic; Victor Tapson; Pascal J Goldschmidt-Clermont; Chunming Dong
Journal:  Circulation       Date:  2008-11-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.